Scotland Approves Linzagolix for Endometriosis Treatment, Expanding Access Across UK
Key Insights
The Scottish Medicines Consortium (search) has approved linzagolix with add-back therapy as a new treatment option for adult women with endometriosis (search) who have previously undergone medical or surgical treatment.
The approval aligns NHS Scotland with the rest of the UK, where linzagolix has already been approved by NICE for use in England, Wales and Northern Ireland.
Linzagolix is a once-daily GnRH receptor (search) antagonist that works by suppressing estrogen and has shown statistically significant reduction in painful periods and pelvic pain in clinical trials.
The Scottish Medicines Consortium (search) (SMC) has approved linzagolix with add-back therapy (ABT) for treating endometriosis (search) in adult women of reproductive age, providing Scottish patients with a new therapeutic option that aligns NHS Scotland with treatment availability across the rest of the UK.
The once-daily oral medication is specifically approved for women who have previously undergone medical or surgical treatment for endometriosis (search). This decision follows the National Institute for Health and Care Excellence (search) (NICE) approval of linzagolix for use in England, Wales and Northern Ireland, ensuring consistent access to the treatment across the UK.
Clinical Impact and Patient Population
Endometriosis (search) affects around one in ten women of reproductive age in the UK, causing chronic pelvic pain, painful menstruation and significant impacts on quality of life. The condition occurs when the lining of the womb grows outside the uterus, inducing painful symptoms and serving as a primary cause of infertility. Despite affecting approximately 200 million women worldwide, endometriosis currently has no cure.
Dr Lucky Saraswat, Consultant Gynaecologist and Honorary Senior Lecturer at the University of Aberdeen, emphasized the clinical significance: "As the need for more individualised approaches to endometriosis (search) management becomes increasingly clear, the availability of an additional therapeutic option represents an important advance. It is encouraging to see women in Scotland gaining access to new treatment options, and I hope ongoing research will continue to broaden the choices available."
Mechanism of Action and Clinical Evidence
Linzagolix belongs to a class of medications called gonadotrophin releasing hormone (GnRH) receptor antagonists. The drug works by suppressing estrogen which, depending on the dose, can reduce bleeding or stop periods altogether. Clinical trials have demonstrated that linzagolix causes a statistically significant reduction in painful periods and general pelvic pain, with fewer side effects than GnRH agonists, which are also used to manage endometriosis (search).
Preclinical studies characterized the pharmacological profile in cynomolgus monkeys, where linzagolix administration effectively suppressed hormone surges and ceased or prolonged menstrual cycles. Research concluded in 2022 that the drug "had potential as a novel agent for reproductive-age women suffering from sex hormone-dependent diseases."
Treatment Landscape and Unmet Need
Current treatment options for endometriosis (search) remain limited, including painkillers, hormonal contraceptives and surgery to remove lesions. However, these options are often inadequate and, in many cases, aren't suitable for patients due to existing medical conditions, pregnancy or because of the risk of side-effects or complications.
Women's Health Minister Baroness Merron described the potential impact: "This could be a game-changer for thousands of women battling endometriosis (search), which can be a debilitating and life-limiting condition. After years of neglect in women's health, we are turning the tide – backing new treatments like linzagolix, cutting diagnosis times and slashing waiting lists."
Industry and Patient Advocacy Response
Sandy Lindsey, UK General Manager at Theramex, highlighted the treatment gap: "There are too many women who are living with pain due to their endometriosis (search). With the SMC approval of linzagolix we can now offer an additional treatment option to women in Scotland, empowering clinicians and patients with more choices. This approval by the SMC is an important step on a much longer journey towards access to improved treatment for endometriosis across the UK."
Emma Cox, Chief Executive at Endometriosis UK (search), welcomed the development: "Endometriosis UK welcomes the addition of Linzagolix to the range of approved treatments for endometriosis (search) in Scotland. It's vital patients are able to make informed choices about what treatment options are right for them."
Broader Therapeutic Applications
Beyond endometriosis (search), linzagolix has demonstrated potential for treating other sex hormone-dependent diseases. In June 2022, it became the first approved oral therapy in the European Union for treating moderate to severe symptoms of uterine fibroids (search) in adult women of reproductive age. Research in animal models has also indicated potential applications for benign prostatic hyperplasia (search) and polycystic ovary syndrome (search).